Viread Oral Powder Generic Name & Formulations
Tenofovir disoproxil fumarate 40mg per 1g pwd.
Nucleotide analogue (HIV-1 and HBV reverse transcriptase inhibitor).
Tabs—30; Oral pwd—60g (w. dosing scoop)
Viread Oral Powder Indications
HIV-1 infection, in combination with other antiretroviral agents. Chronic hepatitis B virus (HBV).
Viread Oral Powder Dosage and Administration
Test for HBV and HIV-1 infection prior to initiation. May use tabs or oral pwd (if unable to swallow). Mix oral pwd with 2–4oz of soft food not requiring chewing (eg, applesauce, baby food, yogurt). HIV or HBV (≥35kg): 300mg once daily. Renal impairment: CrCl 30–49mL/min: 300mg every 48hrs; CrCl 10–29mL/min: 300mg every 72–96hrs; hemodialysis: 300mg every 7 days or after a total of 12hrs of dialysis; CrCl <10mL/min: not recommended.
Test for HBV and HIV-1 infection prior to initiation. <2yrs (<10kg): not established. Mix oral pwd with 2–4oz of soft food not requiring chewing (eg, applesauce, baby food, yogurt). HIV or HBV: Oral pwd (≥2yrs [≥10kg] or Tabs ≥2yrs [≥17kg]): 8mg/kg once daily; max 300mg/day. For additional oral pwd dosing based on body wt: see full labeling. Tabs (if able to swallow): ≥2yrs (17–<22kg): 150mg once daily; (22–<28kg): 200mg once daily; (28–<35kg): 250mg once daily; (≥35kg): 300mg once daily.
Viread Oral Powder Contraindications
Viread Oral Powder Boxed Warnings
Post-treatment severe acute exacerbation of hepatitis B.
Viread Oral Powder Warnings/Precautions
Discontinuation of anti-HBV therapy may be associated with severe acute exacerbations of hepatitis B. Closely monitor HBV-infected patients for several months after stopping treatment; if appropriate, anti-HBV therapy may be warranted (esp. in those with advanced liver disease or cirrhosis). Suspend therapy if lactic acidosis or pronounced hepatotoxicity (eg, hepatomegaly, steatosis) occurs. Assess SCr, estimated CrCl, urine glucose, urine protein in all patients, and serum phosphorus (in chronic kidney disease) before initiating and during therapy. History of pathologic fracture or risk factors of osteoporosis or bone loss: consider monitoring bone mineral density (BMD); calcium/vitamin D supplement may be beneficial. Pregnancy. Nursing mothers: not recommended in HIV-1.
Viread Oral Powder Pharmacokinetics
Viread Oral Powder Interactions
Concomitant adefovir dipivoxil for chronic HBV: not recommended. Avoid concomitant or recent use of nephrotoxic agents. Potentiates didanosine levels; monitor closely. Monitor drugs that reduce renal function or compete for renal tubular secretion (eg, cidofovir, acyclovir, valacyclovir, ganciclovir, valganciclovir, aminoglycosides, high-dose or multiple NSAIDs). Concomitant atazanavir: must give with ritonavir. Potentiated by concomitant lopinavir/ritonavir, ritonavir-boosted atazanavir or darunavir, ledipasvir/sofosbuvir, sofosbuvir/velpatasvir; monitor for toxicity (see full labeling).
Viread Oral Powder Adverse Reactions
Rash, diarrhea, headache, pain, depression, asthenia, nausea, insomnia, dizziness, pyrexia, abdominal pain, vomiting, pruritus; decreased BMD, new onset or worsening renal impairment, immune reconstitution syndrome.
Viread Oral Powder Clinical Trials
Viread Oral Powder Note
Register pregnant patients exposed to tenofovir DF by calling (800) 258-4263.
Viread Oral Powder Patient Counseling